NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 239)
Posted On: 09/07/2018 4:23:36 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Strategic Additions to Patent Portfolio
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a drug delivery platform innovator, this morning announced strategic additions to its patent portfolio. Per the update, three new Australian patents were recently granted to Lexaria by the Australian Patent Office, bringing the company’s total number of issued patents to eight, including four in the U.S. and four in Australia. All eight patents are within Lexaria’s first patent family, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” Additionally, the company received two new Notices of Allowance from the U.S. Patent & Trademark Office for pending patent applications, and it expects to receive the corresponding U.S. patents prior to year-end 2018. To date, Lexaria has filed over 50 patent applications across nine patent families. With this large collection of filings and at least seven more patent families planned, Lexaria intends to disclose material patent filings and issuances moving forward, but not each patent-related development.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a drug delivery platform innovator, this morning announced strategic additions to its patent portfolio. Per the update, three new Australian patents were recently granted to Lexaria by the Australian Patent Office, bringing the company’s total number of issued patents to eight, including four in the U.S. and four in Australia. All eight patents are within Lexaria’s first patent family, “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof.” Additionally, the company received two new Notices of Allowance from the U.S. Patent & Trademark Office for pending patent applications, and it expects to receive the corresponding U.S. patents prior to year-end 2018. To date, Lexaria has filed over 50 patent applications across nine patent families. With this large collection of filings and at least seven more patent families planned, Lexaria intends to disclose material patent filings and issuances moving forward, but not each patent-related development.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼